Greenleaf Trust Has $2.11 Million Holdings in McKesson Co. (NYSE:MCK)

Greenleaf Trust increased its position in shares of McKesson Co. (NYSE:MCKFree Report) by 1.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,844 shares of the company’s stock after acquiring an additional 54 shares during the quarter. Greenleaf Trust’s holdings in McKesson were worth $2,106,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in MCK. Aspire Private Capital LLC lifted its holdings in shares of McKesson by 3.2% during the 3rd quarter. Aspire Private Capital LLC now owns 1,957 shares of the company’s stock valued at $851,000 after purchasing an additional 60 shares in the last quarter. Raymond James & Associates boosted its stake in McKesson by 0.4% in the 3rd quarter. Raymond James & Associates now owns 144,396 shares of the company’s stock valued at $62,791,000 after purchasing an additional 533 shares during the period. Brown Advisory Inc. boosted its stake in McKesson by 4.8% in the 2nd quarter. Brown Advisory Inc. now owns 3,844 shares of the company’s stock valued at $1,643,000 after purchasing an additional 175 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in McKesson by 16.0% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,148,794 shares of the company’s stock valued at $2,238,953,000 after purchasing an additional 708,438 shares during the period. Finally, C WorldWide Group Holding A S bought a new stake in shares of McKesson during the 2nd quarter valued at $2,151,000. Institutional investors and hedge funds own 82.69% of the company’s stock.

McKesson Stock Performance

Shares of MCK stock opened at $501.35 on Monday. McKesson Co. has a 52-week low of $331.75 and a 52-week high of $519.75. The firm has a market capitalization of $65.88 billion, a PE ratio of 22.72, a PEG ratio of 1.70 and a beta of 0.44. The stock has a fifty day simple moving average of $475.11 and a two-hundred day simple moving average of $451.85.

McKesson (NYSE:MCKGet Free Report) last released its quarterly earnings data on Wednesday, February 7th. The company reported $7.74 EPS for the quarter, beating the consensus estimate of $7.05 by $0.69. McKesson had a net margin of 0.99% and a negative return on equity of 262.63%. The business had revenue of $80.90 billion during the quarter, compared to the consensus estimate of $77.93 billion. During the same quarter in the prior year, the firm earned $6.90 EPS. The business’s revenue was up 14.8% on a year-over-year basis. On average, sell-side analysts forecast that McKesson Co. will post 27.58 EPS for the current fiscal year.

McKesson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 1st. Shareholders of record on Friday, March 1st will be issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a dividend yield of 0.49%. The ex-dividend date of this dividend is Thursday, February 29th. McKesson’s dividend payout ratio (DPR) is presently 11.24%.

Insider Activity at McKesson

In related news, CEO Brian S. Tyler sold 14,026 shares of the stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $480.00, for a total value of $6,732,480.00. Following the completion of the transaction, the chief executive officer now owns 43,445 shares of the company’s stock, valued at approximately $20,853,600. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.21% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on MCK shares. StockNews.com cut McKesson from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 4th. UBS Group upped their target price on McKesson from $525.00 to $559.00 and gave the company a “buy” rating in a research report on Monday, January 29th. TD Cowen upped their target price on McKesson from $508.00 to $563.00 and gave the company an “outperform” rating in a research report on Monday, December 11th. JPMorgan Chase & Co. increased their price target on McKesson from $495.00 to $514.00 and gave the stock an “overweight” rating in a report on Friday, November 17th. Finally, Citigroup raised their target price on McKesson from $530.00 to $575.00 and gave the company a “buy” rating in a report on Thursday. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, McKesson has an average rating of “Moderate Buy” and an average target price of $511.54.

View Our Latest Stock Report on McKesson

McKesson Profile

(Free Report)

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

See Also

Institutional Ownership by Quarter for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.